ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Fibroblasts, Dermal"

  • Abstract Number: 0954 • ACR Convergence 2023

    Non-canonical WNTA Promotes Cytoskeletal Rearrangement and Integrin Alpha V Clustering via JNK and ROCK to Control the Activation of Latent TGFβ

    Thuong Trinh-Minh1, Chih-Wei Chen2, Cuong Tran Manh1, yi-nan Li1, Honglin Zhu3, Debomita Chakraborty4, Yun Zhang1, Simon Rauber5, Clara Dees5, Christina Bergmann6, Alexander Kreuter7, Christiane Reuter8, Florian Groeber-Becker8, Beate Eckes9, Oliver Distler10, Andreas Ramming11, Georg Schett12 and Joerg Distler1, 1Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, 23 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, 33 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany. 5 Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, China, 43 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 53 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, 6Department Internal Medicine, University Hospital Erlangen, Germany, Erlangen, Germany, 7Clinic for Dermatology, Venereology and Allergology, HELIOS St. Elisabeth Clinic, Oberhausen, Germany, 8Translational Center for Regenerative Therapies, Fraunhofer Institute for Silicate Research (ISC) Würzburg, Würzburg, Germany, 9Translational Matrix Biology, University of Cologne, Cologne, Germany. 9 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Köln, Germany, 10Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 11Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 12Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder with vasculopathy, inflammation, and fibrosis of the skin and organs. Fibrosis is caused by the abnormal…
  • Abstract Number: 0957 • ACR Convergence 2023

    Rationale for Targeting Insulin-like Growth Factor Signalling in Systemic Sclerosis

    Voon Ong1, Shiwen Xu2, Li Xue2, Brajesh Kumar3 and Christopher Denton2, 1UCL Medical School Royal Free Campus, London, United Kingdom, 2University College London, London, United Kingdom, 3Horizon Therapeutics, South San Francisco, CA

    Background/Purpose: Previous studies have shown that insulin like growth factor (IGF) pathways may promote extracellular matrix deposition and be upregulated in systemic sclerosis (SSc). Teprotumumab,…
  • Abstract Number: 0960 • ACR Convergence 2023

    MiR-3606-3p Alleviates Skin Fibrosis by Suppressing Fibroblast Inflammation and Migration via Inhibiting GAB1 and ITGAV

    yahui chen1, Mengkun shi1, Wei Wang1, Chenyi Shi1, Xueyi Xia1, wenyu Wu2, Jiucun Wang3 and Xiangguang Shi3, 1Fudan University, Shanghai, China, 2Huashan Hospital, Shanghai, China, 3Shanghai, Shanghai, China

    Background/Purpose: Systemic sclerosis (SSc) and keloid are typical skin fibrotic diseases with unclear epigenetic mechanisms and clinical targets. As an important epigenetic regulatory factor, microRNAs…
  • Abstract Number: 0085 • ACR Convergence 2023

    Fibroblasts Promote Upregulation of Cannabinoid Type 2 Receptor on Inflammatory Cells in Dermatomyositis

    DeAnna Diaz1, Muhammad Bashir1, Rohan Dhiman2, Avital Baniel1, Julianne Kleitsch1, Rachita Pandya1, Meena Sharma1, Thomas Vazquez1, Ming-Lin Liu2, Mariko Momohara2 and Victoria Werth3, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, PA

    Background/Purpose: Dermatomyositis (DM) is a chronic, systemic autoimmune disease affecting the skin, muscle, and lungs. The activation of CB2R has been shown to reduce several,…
  • Abstract Number: 0963 • ACR Convergence 2023

    Anti-Topoisomerase Antibody in dcSSc: Unravelling Its Intracellular Effects in Systemic Sclerosis

    Maithri Aspari1, Josephine Geertsen Keller-Socin1, Stinne Greisen2, Esben Naeser3, Klaus Soendergaard4, Birgitta R Knudsen5, Voon Ong6, Christopher Denton7, David Abraham7 and Bent Deleuran1, 1Aarhus University, Aarhus, Denmark, 2Aarhus University/Aarhus University Hospital, Aarhus, Denmark, 3Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 4Aarhus University Hospital, Aarhus, Denmark, 5Institute for molecular Biology, Aarhus University, Aarhus, Denmark, 6UCL Medical School Royal Free Campus, London, United Kingdom, 7University College London, London, United Kingdom

    Background/Purpose: The presence of autoantibodies, especially directed towards topoisomerase I (ATA), in diffuse cutaneous Systemic Sclerosis (dcSSc) is known to be associated with severe clinical…
  • Abstract Number: 0787 • ACR Convergence 2023

    Understanding Distinct Resident and Migratory Fibroblast Populations in Systemic Sclerosis Skin Through Single-cell RNAseq and Immunohistochemistry

    Kristina Clark1, Shiwen Xu2, Voon Ong3, Christopher Buckley4 and Christopher Denton2, 1Barts Health NHS Trust, London, United Kingdom, 2University College London, London, United Kingdom, 3UCL Medical School Royal Free Campus, London, United Kingdom, 4University of Oxford, Oxford, United Kingdom

    Background/Purpose: We previously described distinct migratory and resident fibroblast populations from lesional skin biopsies in SSc patients. Both populations are profibrotic compared with those from…
  • Abstract Number: 0964 • ACR Convergence 2023

    Systemic Sclerosis (SSc) Dermal Fibroblasts Show Shortened Primary Cilia Due to Aberrant Aurora a Kinase Activation Independently of Transforming Growth Factor β Signalling

    Rebecca Wells1, Rebecca Ross2, Alex Timmis1, Ioanna Georgiou1, Colin Johnson1, Natalia Riobo-Del Galdo1 and Francesco Del Galdo3, 1University of Leeds, Leeds, United Kingdom, 2Medicine and Health, University of Leeds, Leeds, United Kingdom, 3University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom

    Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disorder characterised by abnormal activation of tissue fibroblasts, resulting in tissue and vascular fibrosis of the skin and…
  • Abstract Number: 0892 • ACR Convergence 2023

    Single-Cell RNA Sequencing Reveals Keratinocytes and Fibroblasts Drive Hippo and TGFb Dysregulation and Fibrosis in Epidermal Overexpression of VGLL3 in Cutaneous Lupus

    Mehrnaz Gharaee-Kermani1, Allison Billi1, Jacob Martens1, Marisa Hildebrandt1, Amanda Victory1, Mitra Maz2, Shannon Loftus1, J. Michelle Kahlenberg1 and Johann E. Gudjonsson1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan Medical School, Ann Arbor, MI

    Background/Purpose: Fibrosis is characterized by collagen deposition, fibro/myofibroblast (MYOFB) accumulation, and extracellular matrix remodeling. In some subtypes of cutaneous lupus erythematosus (CLE), particularly discoid lupus…
  • Abstract Number: 1663 • ACR Convergence 2023

    Clinically Severe Systemic Sclerosis Skin Harbors Inflammatory Fibroblasts Associated with Lymphocytes and Plasmacytoid Dendritic Cells

    Kimberly Lakin1, Robert Spiera2, Yaxia Zhang1, David Oliver1, Aliza Bloostein1, Hiranmayi Ravichandran3, Niroshana Anandasabapathy3, Franck Barrat1, Jessica Gordon1 and Dana Orange4, 1Hospital for Special Surgery, New York, NY, 2Hosptial for Special Surgery, New York, NY, 3Weill Cornell Medical College, New York, NY, 4The Rockefeller University, New York, NY

    Background/Purpose: We have previously shown that skin fibroblast activation is related to clinical severity and resolves with improvement in diffuse systemic sclerosis (dcSSc). The immune…
  • Abstract Number: 0934 • ACR Convergence 2023

    Anti-fibrotic Effects of MT-5562, a Novel Potent Selective Autotaxin Inhibitor, in Preclinical Studies: Roles of Lysophosphatidic Acid in Autoimmune Diseases and Clues to Treat Skin and Lung Fibrosis in Systemic Sclerosis

    Hiroshi Matsuura1, Masahiro Kondo1, Ryoko Ohno1, Akina Ishii1, Mariam Piruzyan1, Kaori Funayama1, Yuuichi Ono1, Atsushi Iwamura1, Tadashi Endo1, Tomoya Akashi1, Taizo Tomari2, Noriko Uchiyama2, Noriyasu Seki1, Kenji Chiba1, Gabriela Kania3, Przemyslaw Blyszczuk4, Oliver Distler5, Tsutomu Takeuchi6 and Yuko Kaneko7, 1Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, 2Mitsubishi Tanabe Pharma Corporation, Fujisawa, Japan, 3University of Zurich, Zurich, Switzerland, 4Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 5Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 6Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 7Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Targeted small-molecule therapies to autotaxin (ATX), the lysophosphatidic acid (LPA)-producing enzyme, have been shown to be potentially effective in systemic sclerosis (SSc), but the…
  • Abstract Number: 1664 • ACR Convergence 2023

    Fibroblast Specific Interferon Regulatory Factor 7 (IRF7) Expression Is a Key Link Between Type I Interferon Activation and the Exaggerated Dermal and Pulmonary Fibrosis in Systemic Sclerosis

    Minghua Wu1, Jerry Alonso2, Julio charles2, Brian Skaug2, Tingting Mills3, Maureen Mayes2 and Shervin Assassi4, 1Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, 2Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, 3Biochemistry Department, University of Texas McGovern Medical School, Houston, TX, 4University of Texas McGovern Medical School at Houston, Houston, TX

    Background/Purpose: A prominent interferon (IFN) activation signature has been observed at the peripheral blood and end-organ levels in systemic sclerosis (SSc). However, the mechanisms by…
  • Abstract Number: 0936 • ACR Convergence 2023

    Impaired DNA Repair Responses Activate a Novel FOXO1-dependent Metabolic Remodelling in Patients with Progressive Systemic Sclerosis to Promote Fibrosis

    Lamia Khan, Desiree Redmond, Muhammad Elezzabi, Robert Gniadecki, Jan Willem Cohen Tervaert and Mohamed Osman, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Systemic sclerosis (SSc) is a deadly disease characterized by immune dysregulation, vasculopathy, and fibrosis. SSc is the most lethal rheumatic disease associated with the…
  • Abstract Number: 2367 • ACR Convergence 2023

    Characterization of the SFRP4+ PRG4+ Fibroblast Subpopulation in the Dermis of Healthy Skin and Its Relationship to SFRP4+ PRG4- Myofibroblasts in the Skin of Patients with Systemic Sclerosis

    Banafsheh Nazari1, Tracy Tabib2 and Robert Lafyatis2, 1University of Pittsburgh, Atlanta, GA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Systemic sclerosis (SSc) is a debilitating autoimmune disease characterized by extensive fibrosis affecting multiple organs. The fibrosis arises from the excessive production of collagen…
  • Abstract Number: 0941 • ACR Convergence 2023

    RUNX1 Expression and Binding Site Accessibility Is Associated with Increased Disease Severity in Systemic Sclerosis

    Rezvan Parvizi1, Zhiyun Gong1, Dillon Popovich1, Tamar Abel2, Helen Jarnagin1, Madeline Morrisson1, Tammara Wood2, Jonathan Garlick3, Monique Hinchcliff4, Patricia Pioli1 and Michael Whitfield1, 1Geisel School of Medicine at Dartmouth, Hanover, NH, 2Dartmouth College, Hanover, NH, 3Tufts University School of Dental Medicine, Boston, MA, 4Yale School of Medicine, Westport, CT

    Background/Purpose: Runt-related transcription factor 1 (RUNX1) is a member of the core-binding factor family that regulates proliferation, differentiation, and cell survival in multiple cell lineages.…
  • Abstract Number: 007 • 2023 Pediatric Rheumatology Symposium

    Single Cell RNA Sequencing Analysis of the Skin to Evaluate the Effect of Autologous Stem Cell Transplant on Fibroblast Populations in Juvenile Onset Systemic Sclerosis

    Claire Cheng, Giffin Werner, Anwesha Sanyal and Kathryn Torok, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Juvenile systemic sclerosis (JSSc) is a rare autoimmune disease associated with high morbidity. Inflammatory driven multi-organ fibrosis is similar to adult-onset SSc, with 40%…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology